Dr Enzo Ranieri BSc, Ph.D
Head of Biochemical Genetics, SA Pathology
Dr Janice Fletcher MBBS, BSc, MD, FRACP, FRCPA
Clinical Director of Genetics and Molecular Pathology, Deputy Executive Director of SA Pathology
Peter Sharp MHGSA
Senior Medical Scientist, Biochemical Genetics, SA Pathology
Dr Steven Ramsay BSc, Ph.D, Ph.D
Consultant Medical Scientist, Biochemical Genetics, SA Pathology
Medvet-supported researchers have discovered a range of novel biomarkers present in maternal blood that indicate the risk of Down Syndrome in the foetus. This new diagnostic approach shows exceptional accuracy of detection at only 9-10 weeks’ gestation. This contrasts with current approaches that are unable to display the same accuracy until within 13-26 weeks’ gestation. At that late stage, some diagnostics pose a serious risk to the health of the child. With interest from major diagnostic companies, Medvet is supporting a validation trial of the procedure, which could revolutionise diagnosis in utero.
Along with assisting the researchers with protecting this exciting technology, Medvet has aided in commercial assessment, identifying avenues to market. This has generated a number of key commercial options and markets. Medvet has attracted and involved international investment from key partners, and financed the inclusion of new research scientists in the project, with a licence pending for this exciting new technology.